More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

So which mergers and acquisitions among pharmaceutical companies have made the mark thus far in 2018? DCAT Value Chain Insights takes an inside look. Two $60-billlion deals top the list. First is Bayer’s $63-billion acquisition of Monsanto, an...

Demand for capacity has driven the market for contract development and manufacturing (CDMO) services, but capacity alone will not be enough in the near term. CDMO strategies need to look beyond today’s opportunities and brace for changing market...

Bayer’s completion of its $63-billion acquisition of Monsanto, an agrochemical and seed company, fortifies the company’s plan of becoming a pure-play life-sciences company focused on pharmaceuticals, crop science, consumer healthcare, and animal...

In 2017, the FDA approved a record 1,027 abbreviated new drug applications, 843 of which were fully approved, and is working to further facilitate generic-drug development and approval. Reauthorization of the Generic Drug User Fee Amendments...

Fresh from the annual meeting of the American Society of Clinical Oncology in Chicago where pharmaceutical companies highlighted their pipelines and products, what is the outlook for the cancer-drug market, the largest therapeutic area in the...

Fortune released its annual list of the Fortune 500 companies, which rank the companies in the US with the largest revenues. So how did pharmaceutical companies and suppliers score in the 2017 rankings? Johnson & Johnson, the pharmaceutical,...

How can pharmaceutical companies and suppliers best partner to achieve cost-efficiencies and drive value? A preview of DCAT Sharp Sourcing, to be held June 26, highlights best practices. The program features collaborative approaches with insight...